Browse MAP6

Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Golgi apparatus Cell projection, axon Cell projection, dendrite Cytoplasmic vesicle, secretory vesicle membrane Lipid-anchor Cytoplasmic side Note=Localizes predominantly in the proximal part of the axon (By similarity). Preferentially is concentrated on a portion of the microtubule polymer in which tubulin is modified by detyrosination and acetylation and is also resistant to depolymerization induced by both nocodazole and cold (By similarity). In unpolarized neurons, localizes to the Golgi and to secretory vesicles accumulating transiently at the tips of a subset of neurites (By similarity). Following neuronal polarization and during axon outgrowth, accumulates in the axonal growth cone and subsequently localizes throughout the axon (By similarity). Partially localizes to dendrites in mature neurons (By similarity). Colocalizes with neurofilament (NF)-rich inclusions in spinal chord and brain neurons of patients with amyotrophic lateral sclerosis (ALS) (PubMed:14692697).
Domain -
Function

Involved in microtubule stabilization in many cell types, including neuronal cells (By similarity). Specifically has microtubule cold stabilizing activity (By similarity). Involved in dendrite morphogenesis and maintenance by regulating lysosomal trafficking via its interaction with TMEM106B (PubMed:24357581). Regulates KIF5A-mediated axonal cargo transport (By similarity). Regulates axonal growth during neuron polarization (By similarity).

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0016358 dendrite development
GO:0032418 lysosome localization
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0051640 organelle localization
Molecular Function GO:0005516 calmodulin binding
GO:0008017 microtubule binding
GO:0015631 tubulin binding
Cellular Component GO:0005874 microtubule
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAP6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAP6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAP6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5190.0399
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.880.0533
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.260.503
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9090.054
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.4170.418
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2730.895
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2570.645
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4220.612
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8740.307
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3510.0249
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6340.0473
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5720.0039
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAP6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAP6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAP6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAP6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAP6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAP6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAP6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAP6
Namemicrotubule-associated protein 6
Aliases KIAA1878; STOP; FLJ41346; MAP6-N; MTAP6; N-STOP; CTD-2530H12.7; MAP-6; stable tubule-only polypeptide
Chromosomal Location11q13.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAP6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.